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ABSTRACT
Objective: The aim of the present study is to improve the aqueous solubility and develop in situ gelling eye drops of loteprednol etabonate. Beta-
cyclodextrin (β-CD)-assisted solubility enhancement was attempted and phase solubility studies were carried out.
Methods: The kneading technique was used to formulate drug/β-CD inclusion complexes with a ratio of 1:1. In situ gelling ophthalmic sol–gel 
systems were then developed. Ion-sensitive and pH-dependent trigger mechanisms were targeted. The former type was based on increasing gellan 
gum concentration, to formulate three systems F1, F2, and F3. The latter pH-dependent systems were formulated using a constant concentration 
of Carbopol 971P NF and varying concentrations of hydroxypropyl methylcellulose (HPMC) K4 M and HPMC K15M grades giving formulations F4, 
F5, and F6. All six formulations were subjected to physicochemical evaluation for clarity and appearance, texture analysis, pH, viscosity, isotonicity, 
in vitro gelation, drug content determination, and microbiological tests (sterility testing and effectiveness of preservative) which were also conducted.
Results: All the six formulations passed the analytical tests, with F2 and F4 emerging as the optimized formulations. Eight hour in-vitro drug release 
carried out in a fabricated diffusion cell revealed the release to a concentration dependent controlled one. One month stability studies at 40°C and 
75% RH of the optimized formulations proved their robustness.
Conclusion: Extensive studies carried out revealed the optimized formulation for each category of sol-gel systems. Formulations F2 and F4 were 
found to be these optimized formulations.
Keywords: Loteprednol etabonate, Beta-cyclodextrin, Solubility, In situ gelling.
INTRODUCTION
In situ forming gels are formulations that are applied as solutions or 
suspensions and undergo gelation due to physicochemical changes in 
the eye and are triggered by increased temperature, pH, or ionic strength.
Loteprednol etabonate is a topical corticoid anti-inflammatory. It is 
used in ophthalmic solution for the treatment of steroid-responsive 
inflammatory conditions of the eye such as allergic conjunctivitis, 
uveitis, acne rosacea, superficial punctate keratitis, herpes zoster 
keratitis, iritis, cystitis, and selected infective conjunctivitis [1].
Beta-cyclodextrin (β-CD) complexation with loteprednol etabonate 
enhances its solubility. Various methods can be applied to prepare drug/
cyclodextrin complexes, including the solution method, the coprecipitation 
method, neutralization method, the slurry method, the kneading method, 
and the grinding method. In most cases, the presence of at least some water 
is essential for successful complex formation. In solution, cyclodextrin 
complexes are usually prepared by the addition of excess amount of drug 
to an aqueous cyclodextrin solution. The suspension form is equilibrated 
at the desired temperature (which may require periods of up to 1 week 
and then filtered or centrifuged to form clear drug/cyclodextrin complex 
solution). For the preparation of solid complexes, the water is removed 
from the aqueous drug/cyclodextrin solution by evaporation (e.g., spray 
drying) or sublimation (e.g., lyophilization). Topical corticosteroids have 
been used to treat ocular inflammatory conditions and have several 
drawbacks. In situ release products are an alternative [1,2].
MATERIALS AND METHODS
Materials
Loteprednol etabonate was obtained as a free gift sample from Cipla 
Ltd., Verna, Goa. Gellan gum was obtained from Oxford Laboratories, 
Mumbai, India. Carbopol® 971P NF was obtained from Lubrizol 
Advanced Materials India Pvt. Ltd., Mumbai, India. Hydroxypropyl 
methylcellulose (HPMC) K4 M and HPMC K15 M were gifted by Colorcon 




Melting point of drug was done by open capillary method. Drug was 
taken in a glass capillary sealed at one end in a flam and dipped in liquid 
paraffin inside the melting point apparatus [1,2].
Partition coefficient
The partition coefficient of loteprednol etabonate was determined using 
n-octanol and phosphate buffer pH 7.4 as the aqueous phase. The two 
phases were mixed in equal quantities (1:1) saturated with each other on 
a mechanical bath shaker at 32°C for 24 h. To it, 100 mg of drug was added. 
The flask was shaken at 32°C for 6 h to achieve a complete partitioning. 
The two phases were then separated by centrifugation at 100 rpm for 
5 min. The solutions obtained were passed through a membrane filter 
and analyzed spectrophotometrically. The partition coefficient of the 
drug was calculated using the following expression [1-3]:


Drug concentration in n Octanol   K o / w  
Drug concentration in phosphate buffer pH 7.4
Solubility analysis
The solubility profile of loteprednol etabonate was determined using 
modified shake flask method in select suitable solvents. An excess of 
the drug was added to each of the 10 ml of the solvents taken in tubes 
maintained at room temperature. The tubes were shaken (vortex mixed). 
© 2019 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
org/licenses/by/4. 0/) DOI: http://dx.doi.org/10.22159/ajpcr.2019.v12i12.33160
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Aliquot portions of the supernatants were taken, filtered, and suitably 
diluted for quantification of loteprednol etabonate [4].
Calibration curve of loteprednol etabonate in simulated tear fluid 
(STF) phosphate buffer pH 7.4
A stock solution of 1000 μg/ml of loteprednol etabonate was prepared 
in methanol by dissolving 25 mg of loteprednol etabonate in 25 ml of 
methanol. A working standard solution of 100 μg/ml of loteprednol 
etabonate was prepared by diluting 10 ml of the stock solution up to 
100 ml in a volumetric flask using methanol. Using the working standard 
solution, a series of standard solutions of concentration ranging from 
2 to 20 μg/ml were prepared by diluting with STF phosphate buffer 
pH 7.4. The absorbance of the solution was measured at the wavelength 
of maximum absorption against the reference blank and was plotted 
against concentration to obtain the standard calibration curve [3,4].
Compatibility studies
The compatibility studies were done by Fourier-transform infrared (FT-IR) 
spectroscopy and differential scanning calorimetry (DSC) studies [5].
FT-IR spectroscopy
The infrared (IR) absorption spectrum was obtained by preparing a 
simple physical mixture of the drug and the excipient. The mixture was 
then placed on the stage of the instrument and scanned by the passage 
of an IR beam through it. The spectra were scanned over a frequency 
range of 4000–400 cm−1 [5].
DSC
DSC was used as a screening technique for assessing the compatibility 
of the pure drug with the individual solid-state excipients and also when 
in combination. To investigate the possible interactions between the 
components, the DSC curves of pure drug and each individual excipient 
were compared with those of their 1:1 w/w physical mixtures [5].
Preliminary studies
Phase solubility studies
A series of β-CD solutions in concentration ranging from 5 to 50 mM 
were prepared using phosphate buffer pH 7.4 each placed in 10 ml 
volumetric flasks. An excess amount of loteprednol etabonate (20 mg) 
was added and sonicated for 1 h and then vortex mixed at room 
temperature for further 24 h to achieve equilibration.
The suspensions were then filtered through 0.45 µ Millipore filter 
and analyzed spectrophotometrically. The phase-solubility profile of 
loteprednol etabonate in aqueous β-CD solutions was then plotted. It 
consisted of concentration of the drug in the aqueous solution in mM 
on the Y-axis plotted against the increasing concentration of β-CD 
on the X-axis. The association constant (Kc) for the complex formed 
was calculated from the slope of the phase-solubility profile and the 
aqueous solubility of loteprednol (S₀), using the equation.
0
 SlopeKc
S  (1  Slope)


The phase solubility studies were carried out in duplicate and the averages 
of both the trials calculated. The complexation efficiency (CE) was 
calculated from the slope of the phase-solubility diagram using the formula.
0CE  S . Kc
Preparation of loteprednol etabonate β-CD (11) complex
Loteprednol etabonate-β-CD (1:1) molecular inclusion complex 
was prepared by mixing drug and beta-cyclodextrin in mortar. A 1:1 
hydroalcoholic solution of distilled water and methanol was used to 
knead the physical mixture into a paste and dried in a vacuum oven 
for 24 h at a temperature not exceeding 40°C. The complex was then 
evaluated for its solubility in distilled water and STF phosphate buffer 
pH 7.4 [6,7].
Development of optimized placebo in situ gelling systems
The concentrations of polymer to be employed for the development 
of the formulations were deduced by carrying out placebo gelling 
studies. Two types of polymers were evaluated for in situ gelation, 
namely, ion-sensitive gellan gum and pH-dependent Carbopol 971P 
NF. Placebo solutions of the polymers in varying concentrations were 
prepared. While gellan gum was formulated as an aqueous solution 
alone, Carbopol 971P NF was solubilized with varying concentrations 
of HPMC grades in phosphate buffer pH 6.8.
The gelling capacity was determined by placing 1 drop of the formulation 
in a vial containing 3 ml of freshly prepared STF equilibrated at 37°C. 
Gel formation was visually assessed and the time taken for gelation and 
the gel formed to dissolve were noted. In both the cases, the minimum 
concentrations at which the respective polymers showed gelling were 
noted [8].
Formulation and development of optimized ion-triggered and 
pH-dependent in situ gelling ophthalmic solutions
Three formulations each of ion-sensitive GelriteTM gellan gum systems 
and pH-dependent Carbopol 971P NF in combination with HPMC K4 M 
and K15 M were formulated (Table 1). The drug-cyclodextrin complex 
equivalent to 0.5% w/v of loteprednol etabonate was dissolved in 
three-fourth of the vehicle. The solution was then filtered using a 0.45 µ 
membrane filter and vacuum filtration assembly. The polymer and 
viscosity-enhancing agents were added to the solution and hydrated 
overnight. The next day, the solution was slightly agitated using magnetic 
stirrer to achieve uniformity. All the other excipients were added and the 
volume made up using the vehicle. The formulation was then filled in 
10 ml capacity amber-colored glass vials, stoppered with rubber closures, 
and ultimately sealed with aluminum caps. These were then subjected to 
terminal sterilization by autoclaving at 121°C and 15 psi for 20 min.
Evaluation of the in situ gelling ophthalmic systems
Clarity and appearance
The clarity of the developed formulations was visually evaluated against 
a black and white background. The sols were further converted to gels 
using STF and the clarity and physical appearance of the gel were taken 
note of Comstock and DeCory [9].
Texture analysis
The firmness, consistency, and cohesiveness of the formulations were 
assessed based on the flow properties of the sol. The pourability of the 
sol was evaluated so as to determine if the formulation could be easily 
administered in vivo [9].
pH
The pH of the in situ sol ophthalmic formulations was determined 
using calibrated pH meter. The measurements were conducted in 
triplicates [9].
Table 1: Compositions of formulations F1-F6 (%w/v)




≈ 0.5 ≈ 0.5 ≈ 0.5 ≈ 0.5 ≈ 0.5 ≈ 0.5
HPMC K4 M - - - 0.2 - 0.1
HPMC K15 M - - - - 0.2 0.1
Gellan gum 0.5 0.75 1.0 - - -
Carbopol 971P NF 0.3 0.3 0.3
Benzalkonium 
chloride
- - - 0.01 0.01 0.01




q. s q. s q. s q. s q. s q. s
HPMC: Hydroxypropyl methylcellulose
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Viscosity
The viscosity of the formulations was determined using a Brookfield 
viscometer (LVDV-I) fitted with spindle no. 2. The sample was placed 
in sample holder of the sample adapter assembly and the angular 
velocity was gradually increased from 0 to 60 rpm. Then, the hierarchy 
of angular velocity was reversed and the average of the two dial reading 
was considered to calculate the viscosity. The formulations were then 
converted from sol to gel by the addition of STF. The viscosity of samples 
was recorded before and after gelation [9].
In vitro gelation
The time taken for the first detection of gelation and for the time taken 
for the gels so formed to dissolve was noted [9].
Isotonicity
A drop of blood was suitably diluted with the formulation under test 
using red blood corpuscles (RBCs) pipette and observed under an 
optical microscope at ×45. The structure of the RBCs was compared 
with standard marketed preparation containing 0.5% loteprednol 
etabonate to assess if any changes occurred in it [10].
Drug content
The vials containing the formulation were shaken for 2–3 min and 1 ml 
was transferred to a 100 ml volumetric flask and volume was made up 
with STF phosphate buffer pH 7.4. The concentration of loteprednol 
etabonate was determined using ultraviolet–visible spectrophotometer 
after suitable dilution with STF phosphate buffer pH 7.4. The 
measurements were carried out in triplicates [11-13].
In vitro release studies
In vitro drug release studies of the in situ gelling systems were carried 
out using a fabricated diffusion cell. The diffusion cell consisted of a 
donor compartment and a receptor compartment with a cellophane 
membrane mounted between them. The receptor compartment was 
filled with 50 ml of STF phosphate buffer pH 7.4 and stirred at 20–
30 rpm throughout the experiment. The temperature was maintained at 
37±0.5°C. 1 ml of the formulation was placed in the donor compartment 
and 5 ml of the fluid from the receptor compartment was withdrawn at 
definite time intervals and was replaced by an equal volume of receptor 




The sterilized sample was aseptically transferred in Soybean Casein 
Digest Medium for bacteria and fluid thioglycollate medium for fungi. 
After inoculation, the media were incubated for not <14 days, at 30–
35°C for bacteria and 20–25°C for fungi. The media were checked for 
growth at the end of the specified period of time [17,18].
Effectiveness of preservative
The test sample was inoculated with microbial strains and the 
effectiveness of the preservative is determined by its ability to check 
microbial growth. This is done by performing viable count at suggested 
intervals of time. Three strains of microorganism were used for the 
purpose of this study, which were Gram-negative Escherichia coli, 
Gram-positive Staphylococcus aureus, and fungi Candida albicans. The 
medium used was nutrient agar with incubation conditions 30–35°C for 
bacteria and 20–25°C for fungi. The time intervals for viable counting 
were on the 0th, 7th, 14th, and 21st days [19,20].
Stability studies
The formulated ophthalmic sol–gel systems were subjected to repeated 
cycles at temperature 40°C and humidity 75% RH for 30 days and 
checked for any signs of instability, polymeric phase separation, gelling 
capacity, and drug content [21-23].
RESULTS
Preformulation studies
Identification tests (Table 2)
Table 2: Results of identification tests
S. No. Test Standard Observation
1. Melting point 222–224°C Complies
2. Partition coefficient (Ko/w) 3.4 Complies
Solubility analysis (Table 3)
Table 3: Solubility analysis of loteprednol etabonate
S. No. Solvent Observation
1. Distilled water Practically insoluble
2. Simulated tear fluid 
phosphate buffer pH 7.4
Practically insoluble
3. Methanol Freely soluble
4. Ethanol Soluble
5. Dichloromethane Soluble
Standardization of loteprednol etabonate (Fig. 1)
Fig. 1: Calibration curve of loteprednol etabonate
Compatibility studies
FT-IR spectroscopy (Fig. 2)
(Figure 2 is cited on next page)
DSC (Fig. 3)
(Figure 3 is cited on next page)
Preliminary studies
Phase solubility studies (Fig. 4)
Fig. 4: Phase-solubility profile of loteprednol etabonate in 
aqueous medium
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Fig. 2: Fourier transform infrared spectra of (a) loteprednol etabonate, (b) beta-cyclodextrin (β-CD), (c) Carbopol 971P NF, (d) gellan gum, 




Fig. 3 Differential scanning calorimetry scan of (a) loteprednol etabonate, (b) beta-cyclodextrin (β-CD), (c) Carbopol 971P NF, (d) gellan 
gum, (e) hydroxypropyl methylcellulose (HPMC), (f) loteprednol etabonate: β-CD (1:1) complex, (g) Drug-Β-CD (11) Complex+Carbopol 
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Sterility testing (Fig. 9)
Fig. 9: Photograph showing results of sterility tests on 
formulations F2 and F4
Stability studies (Table 5)
Table 5: Stability results






1. F2 None Retained 96.02%




The IR spectra of loteprednol etabonate did not show any significant difference 
from those obtained for their physical mixtures. The results indicate that 
there was no positive evidence of interaction between drug and the polymers, 
more than if any hydrogen bonding, which may have occurred between the 
donating and accepting groups of both the drug and the polymers.
DSC
On comparison, the scans displayed that the physical mixtures of the 
active and various excipients did not show any peaks before the main 
peak in the thermal scan of loteprednol etabonate. Any peaks seen 
before were inherent in the individual thermal scans of the excipients.
Preliminary studies
Phase solubility studies
The phase-solubility profile showed a type of solubility profile, 
indicating that the aqueous solubility of the substrate, i.e., the drug 
increases with the increase in the concentration of the ligand, namely, 
β-CD. The complex here is the first order with respect to ligand and 
first or higher order with respect to substrate. The apparent solubility 
of loteprednol etabonate increased linearly on addition of β-CD up to 
a concentration of 45 mM giving the AL-type phase-solubility profile 
having an average slope of 0.896. Taking the aqueous solubility (S0) 
of the drug 0.0171 mM (0.008 mg/ml), the stability constant KC was 
calculated using the formula.
The stability constant KC was found to be 501.0 M−1 which is very close 
to the mean value of KC for β-CD. It also showed that the complex was 
formed in the ratio 1:1. From the value of the stability constant KC, the 
CE was calculated using the formula. The CE was calculated to be 8.567.
Preparation of loteprednol etabonate-β-CD (1:1) complex
The drug-β-CD 1:1 complex was prepared using the kneading technique. 
Hydroalcoholic solution of distilled water and methanol in the ratio of 
1:1 was used as the binding solvent. Following kneading, the mass was 
oven dried for 24 h in a vacuum oven at a temperature not exceeding 
40°C. Following the drying, the complex was evaluated to check its 
solubility. For this purpose, an amount of the complex equivalent 
Formulation and development of optimized ion-triggered and 
pH-dependent in situ gelling ophthalmic solutions (Fig. 5)
Fig. 5: Formulations F1-F6
Evaluation
Viscosity studies (Fig. 6)
Fig. 6: Viscosity studies of formulation F1-F6 as sols
In vitro gelation and isotonicity (Fig. 7)
Fig. 7: (a) In vitro gelation of formulation F2 (b) isotonicity 
evaluation (i) F2, (ii) F5, (iii) marketed product
Drug content (Table 4)
Table 4: Drug content of formulations F1-F6







In vitro release studies (Fig. 8)
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to the proposed dose of the drug was weighed and dissolved in the 
appropriate amount of vehicle, i.e., distilled water. The test showed that 
almost all the complex completely solubilized in the aqueous media 
with no or negligible residue left behind.
Development of optimized placebo in situ gelling systems
To deduce the concentrations of the polymers to be employed in the 
actual formulation aspect, placebo in situ gelling systems were developed 
and tested. These in situ gels were prepared in varying permutation and 
combinations to determine the best candidates for the formulation. 
While gellan gum was used alone, Carbopol 971P NF was evaluated in 
combination with various concentrations of HPMC grades. This was 
due to the acidic nature of polyacrylic acid that produced strongly 
acidic solutions when used in higher concentrations to achieve desired 
rheology characteristics. Hence, it had to be used in lower concentrations 
and the viscosity compensated by means of HPMC. The vehicle used for 
gellan gum was distilled water while that used for Carbopol 971P NF 
was phosphate buffer pH 6.8. In case of each of the test placebo system, 
the parameters evaluated were the gelling strength (gelling time), gel 
structure and cohesiveness, the clarity, and the gelling capacity.
It was observed that, increase in the polymer concentration  in the liquid 
form, showed increase in viscosity and upon gelation it showed increase 
in cohesiveness of structure and consistency. The effects were similar 
with both the polymers i.e gellan gum and Carbopol 971P NF. While 
gellan gum produced clear gels, the ones made with Carbopol 971P NF 
were milky translucent in appearance. The minimum concentration 
of the gellan gum at which gelation was seen was 0.3% w/v. However, 
the gel produced was loose and watery in consistency and dissolved 
rapidly. The concentrations above 0.3% w/v showed promising results 
and were thus carried forward into the actual formulation.
In case of the polymer Carbopol 971P NF, the concentration of 0.3% w/v 
showed first signs of gelation; however, the gel formed was loose and 
inconsistent. Hence, concentrations above 0.3% w/v in combination of 
0.2%w/v HPMC grades were chosen for further development.
Formulation and development of optimized ion-triggered and 
pH-dependent in situ gelling ophthalmic solutions
Formulations F1, F2, and F3 were based on gellan gum with distilled 
water as the vehicle and aimed at bringing about ion-sensitive 
gelation triggered by the calcium ions in the tear fluid. Formulations 
F4, F5, and F6 were based on combinations of Carbopol 971P NF and 
HPMC grades with phosphate buffer pH 6.8 as the vehicle. The nature 
of polyacrylic acid is such that higher concentrations yield desired 
rheological characteristics and form strongly acidic solutions that can 
be irritating to the eye. To circumvent this, Carbopol 971P NF was used 
in combination with two HPMC grades to enhance the viscosity of the 
formulations without the substantial lowering of the pH. The reasoning 
behind the latter choice was to buffer the formulations into the pH 
range of 6.0–6.5 which would have otherwise been strongly acidic due 
to polyacrylic acid.
Benzalkonium chloride was the preservative of choice for formulations 
F4, F5, and F6. The sensitivity and incompatibility or gellan gum to it, 
however, lead to the use of an alternative preservative in the formulations 
F1, F2, and F3. Upon terminal sterilization, thermoreversible gelling was 
noticed in case of formulations F4, F5, and F6. This was attributed to the 
use of HPMC that undergoes thermoreversible gelation at 40–45°C.
Evaluation of the in situ gelling ophthalmic systems
Clarity and appearance
All the formulations (F1-F6) were found to be free from any solid 
foreign particles. The formulations based on gellan gum were clear 
and transparent in appearance. However, formulations F4, F5, and 
F6 composed of polyacrylic acid and HPMC grades were milky in 
appearance. Upon gelation, the formulations F1, F2, and F3 formed 
clear gels with no precipitation or phase separation. Formulation F4, F5, 
and F6 formed translucent gels when triggered with no precipitation or 
phase separation.
Texture analysis
The firmness, consistency, and cohesiveness of formulation were 
assessed based on the flow properties of the sol. Upon gelation, the 
structure and cohesiveness of the in situ gels were also evaluated.
The pourability of the sol was quite satisfactory exhibiting a smooth 
flow ensuring easy administration of the product through the dropper. 
It was seen that upon standing for long periods of time, formulations 
with the highest concentration of polymer and containing the higher 
grade of viscolizer (HPMC K15 M), namely, F3 and F5 tended to settle. 
However, the application of shear stress brought them back to their 
original consistency. Formulation F6 with equal concentrations of both 
HPMC K4 M and K15 M showed intermediate behavior. In terms of 
pourability, formulations F2 and F4 showed optimum behavior.
Upon gelation, it was seen that the formulation F1 formed a loose watery 
matrix, whereas F2 and F4 with intermediate polymer concentrations 
formed soft but firm gels. Formulation F3, with highest gellan gum 
concentration, formulation F5 composed of maximum concentration 
of the high-grade HPMC K15 M, and formulation F6 containing 
intermediate and equal concentrations of both HPMC grades formed 
rigid hard gels that could discomfort the eye.
pH
The normal ocular pH of the eye ranges from 6 to 8. The formulations 
F1, F2, and F3 containing gellan gum showed a slightly basic pH so the 
final pH was adjusted using 0.1 N HCl. The pH of these formulations fell 
in the range of 7.0–8.0. Due to the strong acidic nature of polyacrylic 
acid, formulation F4, F5, and F6 containing Carbopol 971P NF showed 
pH values in the range of 6.0–6.5.
Viscosity
At non-physiological conditions, the formulations were in a liquid state 
and exhibited low viscosity. This viscosity increased with the increase 
in the polymer concentrations in the formulation. Formulation F1, 
F2, and F3 showed increase in viscosity on account of the increasing 
gellan concentration and so did F4, F5, and F6 due to the combinations 
of polymers used, in the order of F4-F5. Formulation F6 remained 
intermediate between F4 and F5 for it contained half the concentration 
of the higher grade HPMC as compared to F5 and the other half was 
HPMC K4 M. Formulation F5 showed the maximum viscosity due to the 
high concentration of HPMC K15 M.
An increase in the pH to 7.4 caused the solutions to transform into gels 
with high viscosity. The formulations exhibited pseudoplastic rheology 
both in the sol form and on gelation.
In vitro gelation
Formulations F1-F6 retained their gelling time within 60 s or less. The gel 
formed by formulation F1 was found to be loose and watery due to the low 
polymer concentration. Formulations F3, F5, and F6 formed rigid hard gels 
that showed the probability of causing discomfort to the eye. Formulations 
F2 (0.75% w/v gellan gum) and F4 (0.3% w/v Carbopol 971P NF and 
0.2% w/v HPMC K4 M) produced soft but firm and flexible gels malleable 
in accordance of curvature of the eye. In all cases, the gelling was 
instantaneous and the gels so formed lasted for 9–10 h and then dissolved.
Isotonicity
All the formulations F1-F6 were evaluated for their tonicity. The 
reference standard used for comparison was a marketed product 
containing 0.5% w/v loteprednol etabonate. It was seen that all the 
formulations passed the isotonicity test causing neither shrinking nor 
bursting of the red blood cells when mixed with a drop of the individual 
formulations and observed under the microscope.
Drug content
All the formulations F1-F6 were assessed to determine the drug content 
and its uniformity. The formulations showed assay values within the 
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confidence limits of 95–105% with values being closer to the lower 
limit.
The assay values concluded that both the polymers irrespective of their 
trigger mechanisms were capable of forming suitable matrices for the 
entrapment of the drug. Furthermore, it was noted that soaking and 
hydration of the polymer in the drug solution as opposed to soaking 
the polymer in the pure solvent followed by solvation of the drug in the 
polymer solution significantly improved the formulation procedure and 
resulted in better drug content.
In vitro release studies
Eight-hour diffusion studies were carried out on all formulations. 
A fabricated diffusion cell consisting of a donor compartment and 
receptor compartment was used for the study. Samples were withdrawn 
in quantities of 5 ml from the receptor compartment and it was 
subsequently replenished with fresh diffusion medium. The samples 
were analyzed for drug release spectrophotometrically.
The release mechanism was understood to be slow controlled release 
type with an initial immediate burst. It was postulated that upon 
coming in contact with its trigger be it the presence of calcium ions 
or the pH change, each formulation undergoes rigidization and forms 
a tight matrix that entraps the solubilized drug and thus controls its 
release. The initial burst release is explained by the prehydration of the 
polymer during the formulation. It is eminent here to remember that 
the vehicles employed in both kinds of formulations were aqueous in 
nature. Furthermore, the polymers were hydrated in the vehicles for 
a good 24 h. With both the polymers, i.e., gellan and Carbopol having 
hydrophilic properties, the matrices when come in contact with the 
medium, due to the prehydration, the water permeation in them is 
not controlled resulting in the burst release. Over the course of time, 
the release follows a concentration-dependent controlled pattern. The 
immediate burst release was more prominent in formulations F1, F2, 
and F3 due to the highly hydrophilic nature of gellan gum. The release 
studies of each formulation were done in duplicates and triplicates to 
assess the reproducibility and reliability of the data.
In case of gellan gum-based in situ gels, the minimum cumulative 
percentage drug release was shown by formulation F1, i.e., 65.98%, 
whereas in the case of Carbopol 971P NF and HPMC-based formulations, 
F6 showed the minimum release of 70.16%. The overall maximum 
release was shown by formulation F2 composed of 0.75% w/v gellan 
gum.
Microbial tests
Based on the assessment of the results of parameters tested, one 
formulation each, i.e. ion triggered and pH dependent was chosen from 
all formulations and was subjected to microbial tests.
Sterility testing
A total of six tubes were incubated, three of each medium (Soybean 
Casein Digest Medium and Fluid Thioglycollate Medium). While two 
test tubes contained the test sample (formulation) each, the third test 
tube as acted as control. After the completion of the incubation period, 
upon observation, it was seen that the two tubes containing the test 
samples showed no viable growth just as in the case of control. Thus, in 
conclusion, both the test samples passed the sterility testing.
Effectiveness of preservative
The test samples were inoculated with specific cultures, namely, Gram-
positive, Gram-negative, and fungi. Viable counts were taken by pour 
plate method on days 0, 7, 14, and 21. A control of each test sample 
was kept which was subjected to the viable count as in the case of test 
samples. At the end of 21 day period, it was seen that the viable count 
drastically decreased every 7 days and thus the preservatives passed 
as per I.P. limits.
Optimized formulation
Based on the results of the parameters evaluated and thorough 
interpretation of data of in vitro release studies and kinetic modeling, 
two formulations, one based on each in situ gelling polymer, were 
chosen to be optimized formulations.
Formulation F2 based on gellan gum (0.75% w/v) and F4 based on 
polyacrylic acid (0.3% w/v Carbopol 971P NF and 0.2% w/v HPMC 
K4 M) successfully passed all the evaluator tests, suggesting their 
superiority from the counterparts and catapulting their use in further 
carrying stability studies. They were thus optimized formulations.
Stability studies
It was seen that formulation F4 slightly thickened on account of the 
thermoreversible gelling of HPMC. However, the viscosity was retained 
subsequently with no signs of phase separation. Formulation F2 showed 
increase in viscosity on standing independent of the temperature 
and humidity conditions which was restored on application of shear 
stress. This proved the pseudoplastic rheology of the formulation. 
Both the formulations retained their gelling capacity. The assay of the 
formulations F2 and F4 revealed the values to be in the limits 95–105%. 
The stability studies indicated that the formulation was physically and 
chemically stable with no significant change in any of the parameters 
evaluated.
CONCLUSION
To overcome reduced corneal permeability of steroid cyclodextrin, 
inclusion complexes was developed. Aqueous solubility and corneal 
perfusion are increased. β-CD, one of the natural unsubstituted 
cyclodextrins, was employed for solubility enhancement of the drug. 
Two different polymers with different triggering mechanisms were 
chosen. One polymer was gellan gum gelled in the presence of divalent 
and monovalent cations, namely, calcium and sodium present in the 
tear fluid. The second choice was polyacrylic acid (Carbopol 971P NF) 
in combination with two HPMC grades, namely, HPMC K4 M and K15 
M. Eight hour in vitro drug release diffusion studies showed controlled 
release affected by the drug concentration gradient. Formulation 
F2 containing 0.75% w/v gellan gum and F4 containing 0.3% and 
0.2% w/v Carbopol 971P NF and HPMC K4 M, respectively, were found 
to be these optimized formulations.
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